Details of the Drug

General Information of Drug (ID: DMFNH7L)

Drug Name
Pentobarbital
Synonyms
Aethaminalum; Dorsital; Etaminal; Ethaminal; Mebubarbital; Mebumal; Nebralin; Nembutal; Neodorm; Pentabarbital; Pentabarbitone; Pentobarbitale; Pentobarbitalum; Pentobarbitone; Pentobarbiturate; Rivadorm; Pentobarbital calcium; Pentobarbital suppository dosage form; Pentobarbitale [DCIT]; Pentobarbituric acid; Ethyl-propylmethylcarbinylbarbituric acid; Nembutal (TN); Nembutal (VAN); Neodorm (VAN); Neodorm (new); Pentobarbital (VAN); Pentobarbital [USP:INN]; Pentobarbital, Monosodium Salt; Pentobarbitalum [INN-Latin]; Pentobarbitone (VAN); Pentobarbital (USP/INN); (+-)-5-Ethyl-5-(1-methylbutyl)barbituric acid; 5-Ethyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-5-(1-methylbutyl)barbituric acid; 5-Ethyl-5-(1-methylbutyl)malonylurea; 5-Ethyl-5-(sec-pentyl)barbituric acid; 5-ethyl-2-hydroxy-5-(1-methylbutyl)pyrimidine-4,6(1H,5H)-dione; 5-ethyl-5-(pentan-2-yl)pyrimidine-2,4,6(1H,3H,5H)-trione;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione
Indication
Disease Entry ICD 11 Status REF
Insomnia 7A00-7A0Z Approved [1], [2], [3]
Therapeutic Class
Hypnotics and Sedatives
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 226.27
Topological Polar Surface Area (xlogp) 2.1
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Bioavailability
80% of drug becomes completely available to its intended biological destination(s) [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.47 mL/min/kg [5]
Half-life
The concentration or amount of drug in body reduced by one-half in 5 - 50 hours [5]
Metabolism
The drug is metabolized via the hepatic microsomal enzyme system [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 12.61439 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.39% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.91 L/kg [5]
Chemical Identifiers
Formula
C11H18N2O3
IUPAC Name
5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione
Canonical SMILES
CCCC(C)C1(C(=O)NC(=O)NC1=O)CC
InChI
InChI=1S/C11H18N2O3/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)
InChIKey
WEXRUCMBJFQVBZ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4737
ChEBI ID
CHEBI:7983
CAS Number
76-74-4
DrugBank ID
DB00312
TTD ID
D0F0YZ
INTEDE ID
DR1254
ACDINA ID
D01333

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
GABA(A) receptor alpha-1 (GABRA1) TT1MPAY GBRA1_HUMAN Antagonist [8], [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Mephenytoin 4-hydroxylase (CYP2C19)
Main DME 		DEGTFWK CP2CJ_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Pentobarbital
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Suvorexant DM0E6S3 Moderate Increased metabolism of Pentobarbital caused by Suvorexant mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [25]
Eszopiclone DM8RZ9H Moderate Increased metabolism of Pentobarbital caused by Eszopiclone mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [26]
Tasimelteon DMLOQ1V Moderate Increased metabolism of Pentobarbital caused by Tasimelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [27]
ITI-007 DMUQ1DO Major Increased metabolism of Pentobarbital caused by ITI-007 mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [28]
Coadministration of a Drug Treating the Disease Different from Pentobarbital (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylergonovine DMBEX4O Moderate Increased metabolism of Pentobarbital caused by Methylergonovine mediated induction of CYP450 enzyme. Abortion [JA00] [29]
Repaglinide DM5SXUV Moderate Increased metabolism of Pentobarbital caused by Repaglinide mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [30]
Midostaurin DMI6E0R Moderate Increased metabolism of Pentobarbital caused by Midostaurin mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [31]
Gilteritinib DMWQ4MZ Moderate Increased metabolism of Pentobarbital caused by Gilteritinib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [32]
Oliceridine DM6MDCF Major Increased metabolism of Pentobarbital caused by Oliceridine mediated induction of CYP450 enzyme. Acute pain [MG31] [33]
Mitotane DMU1GX0 Minor Increased metabolism of Pentobarbital caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [34]
Donepezil DMIYG7Z Moderate Increased metabolism of Pentobarbital caused by Donepezil mediated induction of CYP450 enzyme. Alzheimer disease [8A20] [35]
Metronidazole DMTIVEN Moderate Increased metabolism of Pentobarbital caused by Metronidazole mediated induction of CYP450 enzyme. Amoebiasis [1A36] [36]
Ivabradine DM0L594 Moderate Increased metabolism of Pentobarbital caused by Ivabradine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [37]
Dronedarone DMA8FS5 Moderate Increased metabolism of Pentobarbital caused by Dronedarone mediated induction of CYP450 enzyme. Angina pectoris [BA40] [38]
Nifedipine DMSVOZT Moderate Increased metabolism of Pentobarbital caused by Nifedipine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [39]
Bedaquiline DM3906J Moderate Increased metabolism of Pentobarbital caused by Bedaquiline mediated induction of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [40]
Buspirone DMBS632 Moderate Increased metabolism of Pentobarbital caused by Buspirone mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [41]
Voriconazole DMAOL2S Moderate Increased metabolism of Pentobarbital caused by Voriconazole mediated induction of CYP450 enzyme. Aspergillosis [1F20] [42]
Montelukast DMD157S Moderate Increased metabolism of Pentobarbital caused by Montelukast mediated induction of CYP450 enzyme. Asthma [CA23] [43]
Aminophylline DML2NIB Moderate Increased metabolism of Pentobarbital caused by Aminophylline mediated induction of CYP450 enzyme. Asthma [CA23] [44]
Tindamax DM3OWT4 Moderate Increased metabolism of Pentobarbital caused by Tindamax mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [36]
Chloramphenicol DMFXEWT Moderate Increased metabolism of Pentobarbital caused by Chloramphenicol mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [45]
Cariprazine DMJYDVK Moderate Increased metabolism of Pentobarbital caused by Cariprazine mediated induction of CYP450 enzyme. Bipolar disorder [6A60] [37]
Lapatinib DM3BH1Y Moderate Increased metabolism of Pentobarbital caused by Lapatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [29]
LY2835219 DM93VBZ Moderate Increased metabolism of Pentobarbital caused by LY2835219 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [46]
Exemestane DM9HPW3 Moderate Increased metabolism of Pentobarbital caused by Exemestane mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [47]
Esterified estrogens DM9KZDO Moderate Increased metabolism of Pentobarbital caused by Esterified estrogens mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [48]
Tucatinib DMBESUA Moderate Increased metabolism of Pentobarbital caused by Tucatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [49]
Alpelisib DMEXMYK Moderate Increased metabolism of Pentobarbital caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [50]
Quinestrol DMJ6H1Z Moderate Increased metabolism of Pentobarbital caused by Quinestrol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [48]
Tamoxifen DMLB0EZ Moderate Increased metabolism of Pentobarbital caused by Tamoxifen mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [51]
Cabazitaxel DMPAZHC Moderate Increased metabolism of Pentobarbital caused by Cabazitaxel mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [52]
Toremifene DMQYUWG Moderate Increased metabolism of Pentobarbital caused by Toremifene mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [53]
Bosutinib DMTI8YE Moderate Increased metabolism of Pentobarbital caused by Bosutinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [54]
Estradiol DMUNTE3 Moderate Increased metabolism of Pentobarbital caused by Estradiol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [48]
Atorvastatin DMF28YC Moderate Increased metabolism of Pentobarbital caused by Atorvastatin mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [55]
Macitentan DMP79A1 Moderate Increased metabolism of Pentobarbital caused by Macitentan mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [56]
Doxercalciferol DM6FG1P Moderate Increased metabolism of Pentobarbital caused by Doxercalciferol mediated induction of CYP450 enzyme. Chronic kidney disease [GB61] [57]
Corticotropin DMP9TWZ Moderate Increased metabolism of Pentobarbital caused by Corticotropin mediated induction of CYP450 enzyme. Chronic kidney disease [GB61] [58]
PF-04449913 DMSB068 Moderate Increased metabolism of Pentobarbital caused by PF-04449913 mediated induction of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [59]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Pentobarbital and Dihydrocodeine. Chronic pain [MG30] [60]
Irinotecan DMP6SC2 Moderate Increased metabolism of Pentobarbital caused by Irinotecan mediated induction of CYP450 enzyme. Colorectal cancer [2B91] [61]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Pentobarbital and Olopatadine. Conjunctiva disorder [9A60] [62]
Drospirenone DM1A9W3 Moderate Increased metabolism of Pentobarbital caused by Drospirenone mediated induction of CYP450 enzyme. Contraceptive management [QA21] [48]
Levonorgestrel DM1DP7T Moderate Increased metabolism of Pentobarbital caused by Levonorgestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [48]
Ulipristal DMBNI20 Moderate Increased metabolism of Pentobarbital caused by Ulipristal mediated induction of CYP450 enzyme. Contraceptive management [QA21] [37]
Levobupivacaine DM783CH Minor Increased metabolism of Pentobarbital caused by Levobupivacaine mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [63]
Propofol DMB4OLE Moderate Additive CNS depression effects by the combination of Pentobarbital and Propofol. Corneal disease [9A76-9A78] [64]
Methoxyflurane DML0RAE Moderate Increased metabolism of Pentobarbital caused by Methoxyflurane mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [65]
Alfentanil DMVO0UB Major Additive CNS depression effects by the combination of Pentobarbital and Alfentanil. Corneal disease [9A76-9A78] [66]
Remifentanil DMZTXCH Major Additive CNS depression effects by the combination of Pentobarbital and Remifentanil. Corneal disease [9A76-9A78] [66]
Oxtriphylline DMLHSE3 Moderate Increased metabolism of Pentobarbital caused by Oxtriphylline mediated induction of CYP450 enzyme. Cough [MD12] [44]
Methadone DMTW6IU Major Additive CNS depression effects by the combination of Pentobarbital and Methadone. Cough [MD12] [67]
Mifepristone DMGZQEF Moderate Increased metabolism of Pentobarbital caused by Mifepristone mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [68]
Osilodrostat DMIJC9X Moderate Increased metabolism of Pentobarbital caused by Osilodrostat mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [69]
Ivacaftor DMZC1HS Moderate Increased metabolism of Pentobarbital caused by Ivacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [70]
Ethanol DMDRQZU Major Additive CNS depression effects by the combination of Pentobarbital and Ethanol. Cystitis [GC00] [71]
Rivaroxaban DMQMBZ1 Moderate Increased metabolism of Pentobarbital caused by Rivaroxaban mediated induction of CYP450 enzyme. Deep vein thrombosis [BD71] [72]
Fluoxetine DM3PD2C Minor Decreased metabolism of Pentobarbital caused by Fluoxetine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [73]
Vilazodone DM4LECQ Moderate Increased metabolism of Pentobarbital caused by Vilazodone mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [74]
Paroxetine DM5PVQE Minor Increased metabolism of Pentobarbital caused by Paroxetine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [75]
Vortioxetine DM6F1PU Moderate Increased metabolism of Pentobarbital caused by Vortioxetine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [76]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Pentobarbital and Esketamine. Depression [6A70-6A7Z] [29]
Griseofulvin DMK54YG Moderate Altered absorption of Pentobarbital caused by Griseofulvin. Dermatophytosis [1F28] [77]
[3H]estrone-3-sulphate DMGPF0N Moderate Increased metabolism of Pentobarbital caused by [3H]estrone-3-sulphate mediated induction of CYP450 enzyme. Discovery agent [N.A.] [78]
Trihexyphenidyl DMB19L8 Moderate Additive CNS depression effects by the combination of Pentobarbital and Trihexyphenidyl. Dystonic disorder [8A02] [79]
Zonisamide DM0DTF7 Moderate Increased metabolism of Pentobarbital caused by Zonisamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [80]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Pentobarbital caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [81]
Carbamazepine DMZOLBI Minor Increased metabolism of Pentobarbital caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [82]
Timolol DM3NXRU Moderate Increased metabolism of Pentobarbital caused by Timolol mediated induction of CYP450 enzyme. Essential hypertension [BA00] [83]
Nicardipine DMCDYW7 Moderate Increased metabolism of Pentobarbital caused by Nicardipine mediated induction of CYP450 enzyme. Essential hypertension [BA00] [39]
Praziquantel DMOU1PK Moderate Increased metabolism of Pentobarbital caused by Praziquantel mediated induction of CYP450 enzyme. Flatworm infection [1F70-1F86] [84]
Bay 80-6946 DMLOS5R Moderate Increased metabolism of Pentobarbital caused by Bay 80-6946 mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [85]
Tazemetostat DMWP1BH Major Increased metabolism of Pentobarbital caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [86]
Solifenacin DMG592Q Moderate Increased metabolism of Pentobarbital caused by Solifenacin mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [87]
Mirabegron DMS1GYT Minor Increased metabolism of Pentobarbital caused by Mirabegron mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [88]
Darifenacin DMWXLYZ Moderate Increased metabolism of Pentobarbital caused by Darifenacin mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [89]
Caspofungin DMGQIPT Moderate Increased metabolism of Pentobarbital caused by Caspofungin mediated induction of CYP450 enzyme. Fungal infection [1F29-1F2F] [90]
Cimetidine DMH61ZB Minor Altered absorption of Pentobarbital caused by Cimetidine. Gastro-oesophageal reflux disease [DA22] [91]
Ripretinib DM958QB Moderate Increased metabolism of Pentobarbital caused by Ripretinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [29]
Sunitinib DMCBJSR Moderate Increased metabolism of Pentobarbital caused by Sunitinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [29]
Avapritinib DMK2GZX Moderate Increased metabolism of Pentobarbital caused by Avapritinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [37]
Brimonidine DMQLT4N Moderate Additive CNS depression effects by the combination of Pentobarbital and Brimonidine. Glaucoma [9C61] [92]
Ergotamine DMKR3C5 Moderate Increased metabolism of Pentobarbital caused by Ergotamine mediated induction of CYP450 enzyme. Headache [8A80-8A84] [29]
Carvedilol DMHTEAO Moderate Increased metabolism of Pentobarbital caused by Carvedilol mediated induction of CYP450 enzyme. Heart failure [BD10-BD1Z] [83]
Digitoxin DMWVIGP Moderate Increased metabolism of Pentobarbital caused by Digitoxin mediated induction of CYP450 enzyme. Heart failure [BD10-BD1Z] [93]
Boceprevir DMBSHMF Moderate Increased metabolism of Pentobarbital caused by Boceprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [94]
Telaprevir DMMRV29 Moderate Increased metabolism of Pentobarbital caused by Telaprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [94]
Rifampin DMA8J1G Minor Increased metabolism of Pentobarbital caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [95]
MK-1439 DM215WE Moderate Increased metabolism of Pentobarbital caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [96]
Delavirdine DM3NF5G Moderate Increased metabolism of Pentobarbital caused by Delavirdine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [97]
Fosamprenavir DM4W9B3 Moderate Increased metabolism of Pentobarbital caused by Fosamprenavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [98]
Fostemsavir DM50ILT Minor Increased metabolism of Pentobarbital caused by Fostemsavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [99]
Tipranavir DM8HJX6 Moderate Increased metabolism of Pentobarbital caused by Tipranavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [98]
Efavirenz DMC0GSJ Moderate Increased metabolism of Pentobarbital caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [100]
Dolutegravir DMCZGRE Minor Increased metabolism of Pentobarbital caused by Dolutegravir mediated induction of UGT. Human immunodeficiency virus disease [1C60-1C62] [101]
Saquinavir DMG814N Moderate Increased metabolism of Pentobarbital caused by Saquinavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [98]
Etravirine DMGV8QU Moderate Increased metabolism of Pentobarbital caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [102]
Rilpivirine DMJ0QOW Moderate Increased metabolism of Pentobarbital caused by Rilpivirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [29]
Amprenavir DMLMXE0 Moderate Increased metabolism of Pentobarbital caused by Amprenavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [98]
Darunavir DMN3GCH Moderate Increased metabolism of Pentobarbital caused by Darunavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [98]
Atazanavir DMSYRBX Moderate Increased metabolism of Pentobarbital caused by Atazanavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [98]
Maraviroc DMTL94F Moderate Increased metabolism of Pentobarbital caused by Maraviroc mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [29]
Ritonavir DMU764S Moderate Increased metabolism of Pentobarbital caused by Ritonavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [98]
Paricalcitol DMYBV3G Moderate Increased metabolism of Pentobarbital caused by Paricalcitol mediated induction of CYP450 enzyme. Hyper-parathyroidism [5A51] [57]
Acebutolol DM0TI4U Moderate Increased metabolism of Pentobarbital caused by Acebutolol mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [83]
Penbutolol DM4ES8F Moderate Increased metabolism of Pentobarbital caused by Penbutolol mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [83]
Losartan DM72JXH Minor Increased metabolism of Pentobarbital caused by Losartan mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [103]
Nebivolol DM7F1PA Moderate Increased metabolism of Pentobarbital caused by Nebivolol mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [83]
Nisoldipine DM7ISKJ Moderate Increased metabolism of Pentobarbital caused by Nisoldipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [39]
Levamlodipine DM92S6N Moderate Increased metabolism of Pentobarbital caused by Levamlodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [39]
Verapamil DMA7PEW Moderate Increased metabolism of Pentobarbital caused by Verapamil mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [104]
Diltiazem DMAI7ZV Moderate Increased metabolism of Pentobarbital caused by Diltiazem mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [105]
Amlodipine DMBDAZV Moderate Increased metabolism of Pentobarbital caused by Amlodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [39]
Felodipine DMOSW35 Moderate Increased metabolism of Pentobarbital caused by Felodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [106]
Tolvaptan DMIWFRL Moderate Increased metabolism of Pentobarbital caused by Tolvaptan mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [37]
Fludrocortisone DMUDIR8 Moderate Increased metabolism of Pentobarbital caused by Fludrocortisone mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [58]
Levothyroxine DMHN027 Moderate Increased metabolism of Pentobarbital caused by Levothyroxine mediated induction of CYP450 enzyme. Hypo-thyroidism [5A00] [37]
Lesinurad DMUR64T Moderate Increased metabolism of Pentobarbital caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [107]
Naloxegol DML0B41 Moderate Increased metabolism of Pentobarbital caused by Naloxegol mediated induction of CYP450 enzyme. Large intestine motility disorder [DB32] [108]
Pemigatinib DM819JF Moderate Increased metabolism of Pentobarbital caused by Pemigatinib mediated induction of CYP450 enzyme. Liver cancer [2C12] [37]
Crizotinib DM4F29C Moderate Increased metabolism of Pentobarbital caused by Crizotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [109]
Ceritinib DMB920Z Moderate Increased metabolism of Pentobarbital caused by Ceritinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [110]
Erlotinib DMCMBHA Moderate Increased metabolism of Pentobarbital caused by Erlotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [111]
Lurbinectedin DMEFRTZ Moderate Increased metabolism of Pentobarbital caused by Lurbinectedin mediated induction of CYP450 enzyme. Lung cancer [2C25] [112]
Osimertinib DMRJLAT Moderate Increased metabolism of Pentobarbital caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [113]
Capmatinib DMYCXKL Moderate Increased metabolism of Pentobarbital caused by Capmatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [114]
Selpercatinib DMZR15V Moderate Increased metabolism of Pentobarbital caused by Selpercatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [37]
Artemether DM48QOT Moderate Increased metabolism of Pentobarbital caused by Artemether mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [29]
Quinine DMSWYF5 Moderate Increased metabolism of Pentobarbital caused by Quinine mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [115]
Mefloquine DMWT905 Moderate Increased metabolism of Pentobarbital caused by Mefloquine mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [116]
Idelalisib DM602WT Moderate Increased metabolism of Pentobarbital caused by Idelalisib mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [117]
GDC-0199 DMH0QKA Moderate Increased metabolism of Pentobarbital caused by GDC-0199 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [118]
IPI-145 DMWA24P Moderate Increased metabolism of Pentobarbital caused by IPI-145 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [119]
Acalabrutinib DM7GCVW Moderate Increased metabolism of Pentobarbital caused by Acalabrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [120]
Ibrutinib DMHZCPO Moderate Increased metabolism of Pentobarbital caused by Ibrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [121]
Ponatinib DMYGJQO Moderate Increased metabolism of Pentobarbital caused by Ponatinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [29]
Vemurafenib DM62UG5 Moderate Increased metabolism of Pentobarbital caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [122]
Selumetinib DMC7W6R Moderate Increased metabolism of Pentobarbital caused by Selumetinib mediated induction of CYP450 enzyme. Melanoma [2C30] [123]
LGX818 DMNQXV8 Moderate Increased metabolism of Pentobarbital caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [124]
Estrone DM5T6US Moderate Increased metabolism of Pentobarbital caused by Estrone mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [48]
Ethinyl estradiol DMODJ40 Moderate Increased metabolism of Pentobarbital caused by Ethinyl estradiol mediated induction of CYP450 enzyme. Menopausal disorder [GA30] [78]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Pentobarbital and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [125]
Dihydroergotamine DM5IKUF Moderate Increased metabolism of Pentobarbital caused by Dihydroergotamine mediated induction of CYP450 enzyme. Migraine [8A80] [29]
Ubrogepant DM749I3 Moderate Increased metabolism of Pentobarbital caused by Ubrogepant mediated induction of CYP450 enzyme. Migraine [8A80] [126]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Pentobarbital and Lasmiditan. Migraine [8A80] [127]
Dihydrotachysterol DMFB97P Moderate Increased metabolism of Pentobarbital caused by Dihydrotachysterol mediated induction of CYP450 enzyme. Mineral deficiency [5B5K] [57]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Pentobarbital and Flibanserin. Mood disorder [6A60-6E23] [128]
Panobinostat DM58WKG Moderate Increased metabolism of Pentobarbital caused by Panobinostat mediated induction of CYP450 enzyme. Multiple myeloma [2A83] [129]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Pentobarbital and Thalidomide. Multiple myeloma [2A83] [130]
Nilotinib DM7HXWT Moderate Increased metabolism of Pentobarbital caused by Nilotinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [131]
Ruxolitinib DM7Q98D Moderate Increased metabolism of Pentobarbital caused by Ruxolitinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [132]
Imatinib DM7RJXL Moderate Increased metabolism of Pentobarbital caused by Imatinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [133]
Dasatinib DMJV2EK Moderate Increased metabolism of Pentobarbital caused by Dasatinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [29]
Modafinil DMYILBE Moderate Increased metabolism of Pentobarbital caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [134]
Rolapitant DM8XP26 Moderate Increased metabolism of Pentobarbital caused by Rolapitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [135]
Bupropion DM5PCS7 Moderate Increased metabolism of Pentobarbital caused by Bupropion mediated induction of CYP450 enzyme. Nicotine use disorder [6C4A] [136]
Entrectinib DMMPTLH Moderate Increased metabolism of Pentobarbital caused by Entrectinib mediated induction of CYP450 enzyme. Non-small cell lung cancer [2C25] [137]
Levomethadyl Acetate DM06HG5 Major Additive CNS depression effects by the combination of Pentobarbital and Levomethadyl Acetate. Opioid use disorder [6C43] [60]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Pentobarbital and Apraclonidine. Optic nerve disorder [9C40] [92]
Olaparib DM8QB1D Moderate Increased metabolism of Pentobarbital caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [29]
Altretamine DMKLAYG Moderate Increased metabolism of Pentobarbital caused by Altretamine mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [138]
Pentazocine DM1XBHS Major Additive CNS depression effects by the combination of Pentobarbital and Pentazocine. Pain [MG30-MG3Z] [66]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Pentobarbital and Dextropropoxyphene. Pain [MG30-MG3Z] [139]
Butorphanol DM5KYPJ Major Increased metabolism of Pentobarbital caused by Butorphanol mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [33]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Pentobarbital and Oxymorphone. Pain [MG30-MG3Z] [66]
Hydromorphone DMHP21E Major Additive CNS depression effects by the combination of Pentobarbital and Hydromorphone. Pain [MG30-MG3Z] [66]
Dezocine DMJDB0Y Major Additive CNS depression effects by the combination of Pentobarbital and Dezocine. Pain [MG30-MG3Z] [66]
Codeine DMJX6ZG Major Additive CNS depression effects by the combination of Pentobarbital and Codeine. Pain [MG30-MG3Z] [66]
Nalbuphine DMOSQGU Major Additive CNS depression effects by the combination of Pentobarbital and Nalbuphine. Pain [MG30-MG3Z] [66]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Pentobarbital and Buprenorphine. Pain [MG30-MG3Z] [140]
Hydrocodone DMQ2JO5 Major Additive CNS depression effects by the combination of Pentobarbital and Hydrocodone. Pain [MG30-MG3Z] [67]
Acetaminophen DMUIE76 Moderate Increased metabolism of Pentobarbital caused by Acetaminophen mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [141]
Meperidine DMX4GND Major Increased metabolism of Pentobarbital caused by Meperidine mediated induction of CYP450 enzyme. Pain [MG30-MG3Z] [37]
Oxycodone DMXLKHV Major Additive CNS depression effects by the combination of Pentobarbital and Oxycodone. Pain [MG30-MG3Z] [33]
Biperiden DME78OA Moderate Additive CNS depression effects by the combination of Pentobarbital and Biperiden. Parkinsonism [8A00] [79]
Procyclidine DMHFJDT Moderate Additive CNS depression effects by the combination of Pentobarbital and Procyclidine. Parkinsonism [8A00] [79]
Pimavanserin DMR7IVC Moderate Increased metabolism of Pentobarbital caused by Pimavanserin mediated induction of CYP450 enzyme. Parkinsonism [8A00] [142]
Macimorelin DMQYJIR Moderate Increased metabolism of Pentobarbital caused by Macimorelin mediated induction of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [143]
Lefamulin DME6G97 Moderate Increased metabolism of Pentobarbital caused by Lefamulin mediated induction of CYP450 enzyme. Pneumonia [CA40] [144]
Betamethasone DMAHJEF Moderate Increased metabolism of Pentobarbital caused by Betamethasone mediated induction of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [58]
Hydrocortisone DMGEMB7 Moderate Increased metabolism of Pentobarbital caused by Hydrocortisone mediated induction of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [58]
Ergonovine DM0VEC1 Moderate Increased metabolism of Pentobarbital caused by Ergonovine mediated induction of CYP450 enzyme. Postpartum haemorrhage [JA43] [29]
Lonafarnib DMGM2Z6 Moderate Increased metabolism of Pentobarbital caused by Lonafarnib mediated induction of CYP450 enzyme. Premature ageing appearance [LD2B] [145]
Progesterone DMUY35B Moderate Increased metabolism of Pentobarbital caused by Progesterone mediated induction of CYP450 enzyme. Preterm labour/delivery [JB00] [48]
Enzalutamide DMGL19D Moderate Increased metabolism of Pentobarbital caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [146]
Darolutamide DMV7YFT Moderate Increased metabolism of Pentobarbital caused by Darolutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [147]
Apremilast DMTWS9E Moderate Increased metabolism of Pentobarbital caused by Apremilast mediated induction of CYP450 enzyme. Psoriasis [EA90] [148]
Riociguat DMXBLMP Moderate Increased metabolism of Pentobarbital caused by Riociguat mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [149]
Everolimus DM8X2EH Moderate Increased metabolism of Pentobarbital caused by Everolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [29]
Axitinib DMGVH6N Moderate Increased metabolism of Pentobarbital caused by Axitinib mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [150]
Tofacitinib DMBS370 Moderate Increased metabolism of Pentobarbital caused by Tofacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [29]
Fenoprofen DML5VQ0 Minor Increased metabolism of Pentobarbital caused by Fenoprofen mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [151]
Dexamethasone DMMWZET Moderate Increased metabolism of Pentobarbital caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [58]
Quetiapine DM1N62C Moderate Increased metabolism of Pentobarbital caused by Quetiapine mediated induction of CYP450 enzyme. Schizophrenia [6A20] [29]
Aripiprazole DM3NUMH Moderate Increased metabolism of Pentobarbital caused by Aripiprazole mediated induction of CYP450 enzyme. Schizophrenia [6A20] [152]
Sufentanil DMU7YEL Major Additive CNS depression effects by the combination of Pentobarbital and Sufentanil. Sensation disturbance [MB40] [66]
Avanafil DM75CXN Moderate Increased metabolism of Pentobarbital caused by Avanafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [153]
Tadalafil DMJZHT1 Moderate Increased metabolism of Pentobarbital caused by Tadalafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [37]
LDE225 DMM9F25 Moderate Increased metabolism of Pentobarbital caused by LDE225 mediated induction of CYP450 enzyme. Skin cancer [2C30-2C37] [154]
Gefitinib DM15F0X Moderate Increased metabolism of Pentobarbital caused by Gefitinib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [111]
Larotrectinib DM26CQR Moderate Increased metabolism of Pentobarbital caused by Larotrectinib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [29]
Methylprednisolone DM4BDON Moderate Increased metabolism of Pentobarbital caused by Methylprednisolone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [58]
Docetaxel DMDI269 Moderate Increased metabolism of Pentobarbital caused by Docetaxel mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [155]
Trabectedin DMG3Y89 Moderate Increased metabolism of Pentobarbital caused by Trabectedin mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [37]
Armodafinil DMGB035 Moderate Increased metabolism of Pentobarbital caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [134]
Prednisolone DMQ8FR2 Moderate Increased metabolism of Pentobarbital caused by Prednisolone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [58]
Norethindrone DMTY169 Moderate Increased metabolism of Pentobarbital caused by Norethindrone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [78]
Taxol DMUOT9V Moderate Increased metabolism of Pentobarbital caused by Taxol mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [156]
Doxorubicin DMVP5YE Moderate Increased metabolism of Pentobarbital caused by Doxorubicin mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [37]
Warfarin DMJYCVW Major Increased metabolism of Pentobarbital caused by Warfarin mediated induction of CYP450 enzyme. Supraventricular tachyarrhythmia [BC81] [157]
Fostamatinib DM6AUHV Moderate Increased metabolism of Pentobarbital caused by Fostamatinib mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [158]
Apixaban DM89JLN Moderate Increased metabolism of Pentobarbital caused by Apixaban mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [159]
Brilinta DMBR01X Moderate Increased metabolism of Pentobarbital caused by Brilinta mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [160]
Cabozantinib DMIYDT4 Moderate Increased metabolism of Pentobarbital caused by Cabozantinib mediated induction of CYP450 enzyme. Thyroid cancer [2D10] [161]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Pentobarbital and Tizanidine. Tonus and reflex abnormality [MB47] [162]
Tacrolimus DMZ7XNQ Moderate Increased metabolism of Pentobarbital caused by Tacrolimus mediated induction of CYP450 enzyme. Transplant rejection [NE84] [29]
Canagliflozin DMFRM1I Moderate Increased metabolism of Pentobarbital caused by Canagliflozin mediated induction of UGT. Type 2 diabetes mellitus [5A11] [29]
Saxagliptin DMGXENV Moderate Increased metabolism of Pentobarbital caused by Saxagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [163]
Linagliptin DMWFJTR Moderate Increased metabolism of Pentobarbital caused by Linagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [164]
Elagolix DMB2C0E Moderate Increased metabolism of Pentobarbital caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [165]
Triamcinolone DM98IXF Moderate Increased metabolism of Pentobarbital caused by Triamcinolone mediated induction of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [58]
Cetirizine DMOMP9U Moderate Additive CNS depression effects by the combination of Pentobarbital and Cetirizine. Vasomotor/allergic rhinitis [CA08] [166]
Propafenone DMPIBJK Minor Increased metabolism of Pentobarbital caused by Propafenone. Ventricular tachyarrhythmia [BC71] [167]
⏷ Show the Full List of 220 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Hydrochloric acid E00015 313 Acidulant
Ethanol E00023 702 Antimicrobial preservative; Penetration agent; Solvent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Sodium hydroxide E00234 14798 Alkalizing agent
Water E00035 962 Solvent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Pentobarbital 50mg/ml solution 50mg/ml Solution Intravenous; Intramuscular
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5480).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 083270.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
9 Effect of barbiturates on polyphosphoinositide biosynthesis and protein kinase C activity in synaptosomes. Neuropharmacology. 1989 Dec;28(12):1317-23.
10 CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):821-5.
11 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
12 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
13 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
14 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
15 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
16 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
17 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
18 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
19 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
20 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
21 Zolpidem, a selective GABA(A) receptor alpha1 subunit agonist, induces comparable Fos expression in oxytocinergic neurons of the hypothalamic paraventricular and accessory but not supraoptic nuclei in the rat.Brain Res Bull.2006 Dec 11;71(1-3):200-7.
22 Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9.
23 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7.
24 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
25 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
26 Product Information. Lunesta (eszopiclone). Sepracor Inc, Marlborough, MA.
27 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
28 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
29 Cerner Multum, Inc. "Australian Product Information.".
30 Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14. [PMID: 12919179]
31 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
32 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
33 Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
34 Product Information. Lysodren (mitotane). Bristol-Myers Squibb, Princeton, NJ.
35 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
36 Gupte S "Phenobarbital and metabolism of metronidazole." N Engl J Med 308 (1983): 529. [PMID: 6823276]
37 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
38 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
39 Hamann SR, Blouin RA, Chang SL, et al "Effects of hemodynamic changes on the elimination kinetics of verapamil and nifedipine." J Pharmacol Exp Ther 231 (1984): 301-5. [PMID: 6491984]
40 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
41 Kivisto KT, Lamberg TS, Neuvonen PJ "Interactions of buspirone with itraconazole and rifampicin: Effects on the pharmacokinetics of the active 1-(2-pyrimidinyl)-piperazine metabolite of buspirone." Pharmacol Toxicol 84 (1999): 94-7. [PMID: 10068153]
42 Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
43 Product Information. Singulair (montelukast). Merck & Co, Inc, West Point, PA.
44 Bukowskyj M, Nakatsu K, Munt PW "Theophylline reassessed." Ann Intern Med 101 (1984): 63-73. [PMID: 6145380]
45 Ambrose PJ "Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate." Clin Pharmacokinet 9 (1984): 222-38. [PMID: 6375931]
46 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
47 Product Information. Aromasin (exemestane) Pharmacia & Upjohn, Kalamazoo, MI.
48 Baciewicz AM "Oral contraceptive drug interactions." Ther Drug Monit 7 (1985): 26-35. [PMID: 2859674]
49 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
50 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
51 Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8. [PMID: 9037249]
52 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
53 Berthou F, Dreano Y, Belloc C, Kangas L, Gautier JC, Beaune P "Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes." Biochem Pharmacol 47 (1994): 1883-95. [PMID: 8204106]
54 Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
55 Bullman J, Nicholls A, Van Landingham K, et al. "Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers." Epilepsia 52 (2011): 1351-8. [PMID: 21635243]
56 Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
57 Product Information. Hectorol (doxercalciferol). Genzyme Corporation, Cambridge, MA.
58 Bartoszek M, Brenner AM, Szefler SJ "Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy." Clin Pharmacol Ther 42 (1987): 424-32. [PMID: 3665340]
59 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
60 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
61 Crews KR, Stewart CF, Jones-Wallace D, et al "Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy." Clin Cancer Res 8 (2002): 2202-9. [PMID: 12114421]
62 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
63 Product Information. Chirocaine (levobupivacaine) Organon, West Orange, NJ.
64 Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
65 Brodeur J, Paquin P, Authier L, Geadah D, Yamauchi M, Cote MG "Influence of phenobarbital pretreatment on methoxyflurane and sodium fluoride nephropathy in Fischer 344 Rats." Toxicol Appl Pharmacol 37 (1976): 349-61. [PMID: 982456]
66 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
67 Bell J, Seres V, Bowron P, Lewis J, Batey R "The use of serum methadone levels in patients receiving methadone maintenance." Clin Pharmacol Ther 43 (1988): 623-9. [PMID: 3378383]
68 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
69 Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
70 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
71 Gupta RC, Kofoed J "Toxological statistics for barbiturates, other sedatives, and tranquilizers in Ontario: a 10-year survey." Can Med Assoc J 94 (1966): 863-5. [PMID: 5929537]
72 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
73 Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions. II." J Clin Psychopharmacol 10 (1990): 213-7. [PMID: 2198298]
74 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
75 Product Information. Paxil (paroxetine). GlaxoSmithKline, Research Triangle Park, NC.
76 Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
77 Busfield D, Child KJ, Atkinson RM, Tomich EG "An effect of phenobarbitone on blood-levels of griseofulvin in man." Lancet 2 (1963): 1042-3. [PMID: 14062729]
78 Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
79 Product Information. Artane (trihexyphenidyl). Lederle Laboratories, Wayne, NJ.
80 Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
81 Kuranari M, Tatsukawa H, Seike M, et al. "Effect of phenytoin on phenobarbital pharmacokinetics in a patient with epilepsy." Ann Pharmacother 29 (1995): 83-4. [PMID: 7711354]
82 Benetello P, Furlanut M "Primidone-carbamazepine interaction: clinical consequences." Int J Clin Pharmacol Res 7 (1987): 165-8. [PMID: 3583497]
83 Branch RA, Herman RJ "Enzyme induction and beta-adrenergic receptor blocking drugs." Br J Clin Pharmacol 17 (1984): s77-84. [PMID: 6146342]
84 Bittencourt PR, Gracia CM, Martins R, et al "Phenytoin and carbamazepine decrease oral bioavailability of praziquantel." Neurology 42 (1992): 492-6. [PMID: 1549207]
85 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
86 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
87 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
88 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
89 Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
90 Product Information. Cancidas (caspofungin) Merck & Co, Inc, West Point, PA.
91 Somogyi A, Thielscher S, Gugler R "Influence of phenobarbital treatment on cimetidine kinetics." Eur J Clin Pharmacol 19 (1981): 343-7. [PMID: 7238562]
92 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
93 Cardoso MT, Carvalhas ML. Effects of phenobarbital on digitoxin metabolism in guinea-pig liver slices. Xenobiotica. 1980;10(10):779-784. [PMID: 7456493]
94 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
95 Richter E, Breimer DD, Zilly W "Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents." Eur J Clin Pharmacol 17 (1980): 197-202. [PMID: 7363932]
96 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
97 Borin MT, Chambers JH, Carel BJ, Gagnon S, Freimuth WW "Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate." Clin Pharmacol Ther 61 (1997): 544-53. [PMID: 9164416]
98 Acosta EP, Henry K, Baken L, Page LM, Fletcher CV "Indinavir concentrations and antiviral effect." Pharmacotherapy 19 (1999): 708-12. [PMID: 10391416]
99 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
100 Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T "Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients." Aids 15 (2001): 71-5. [PMID: 11192870]
101 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
102 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
103 Goldberg MR, Lo MW, Deutsch PJ, Wilson SE, Mcwilliams EJ, Mccrea JB "Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite e-3174." Clin Pharmacol Ther 59 (1996): 268-74. [PMID: 8653989]
104 Rutledge DR, Pieper JA, Mirvis DM "Effects of chronic phenobarbital on verapamil dispostion in humans." J Pharmacol Exp Ther 246 (1988): 7-13. [PMID: 3392664]
105 Borcherding SM, Baciewicz AM, Self TH "Update on rifampin drug interactions." Arch Intern Med 152 (1992): 711-6. [PMID: 1558427]
106 Bahls FH, Ozuna J, Ritchie DE "Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin." Neurology 41 (1991): 740-2. [PMID: 2027492]
107 Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
108 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
109 Cerner Multum, Inc. "Canadian Product Information.".
110 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
111 Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7. [PMID: 17575239]
112 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
113 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
114 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
115 Fabre C, Criddle J, Nolder D, Klein JL "Recrudescence of imported falciparum malaria after quinine therapy: potential drug interaction with phenytoin." Trans R Soc Trop Med Hyg 99 (2005): 871-3. [PMID: 16099004]
116 Product Information. Lariam (mefloquine). Roche Laboratories, Nutley, NJ.
117 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
118 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
119 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
120 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
121 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
122 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
123 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
124 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
125 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
126 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
127 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
128 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
129 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
130 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
131 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
132 Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
133 Bolton AE, Peng B, Hubert M, et al. "Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects." Cancer Chemother Pharmacol 53 (2004): 102-6. [PMID: 14605865]
134 Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
135 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
136 James WA, Lippmann S "Bupropion: overview and prescribing guidelines in depression." South Med J 84 (1991): 222-4. [PMID: 1899294]
137 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
138 Paolini A, D'Incalci M "Effect of phenobarbital pretreatment on the metabolism and antitumor activity of hexamethylmelamine." Cancer Treat Rep 70 (1986): 513-6. [PMID: 3084083]
139 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
140 Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
141 Bock KW, Wiltfang J, Blume R, Ullrich D, Bircher J "Paracetamol as a test drug to determine glucuronide formation in man: effects of inducers and of smoking." Eur J Clin Pharmacol 31 (1987): 677-83. [PMID: 3556375]
142 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
143 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
144 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
145 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
146 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
147 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
148 Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ.
149 Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
150 Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
151 Helleberg L, Rubin A, Wolen RL, et al "A pharmacokinetic interaction in man between phenobarbitone and fenoprofen, a new anti-inflammatory agent." Br J Clin Pharmacol 1 (1974): 371-4. [PMID: 22454912]
152 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
153 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
154 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
155 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
156 Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993.
157 Aggeler PM, O'Reilly RA "Effect of heptabarbital on the response to bishydroxycoumarin in man." J Lab Clin Med 74 (1969): 229-38. [PMID: 4184022]
158 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
159 Product Information. Eliquis (apixaban). Bristol-Myers Squibb Canada Inc, Montreal, IN.
160 Canadian Pharmacists Association.
161 Product Information. Cabometyx (cabozantinib). Exelixis Inc, S San Francisco, CA.
162 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.
163 Product Information. Onglyza (saxagliptin). Bristol-Myers Squibb, Princeton, NJ.
164 Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT.
165 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
166 Product Information. Zyrtec (cetirizine). Pfizer US Pharmaceuticals, New York, NY.
167 Sams RA, Muir WW. Effects of phenobarbital on thiopental pharmacokinetics in greyhounds. Am J Vet Res. 1988;49(2):245-249. [PMID: 3348533]